South Africa Vaccines Market Overview, 2028

South Africa Vaccines Market Overview, 2028

World Health Organization (WHO) has ranked South Africa’s vaccine regulatory system at a functional level of maturity, according to WHO’s global classification system for national medical products regulatory authorities. This recognizes that South Africa has a stable, well-functioning and integrated regulatory system to ensure the quality, safety, and effectiveness of vaccines manufactured, imported or distributed in the country. A strong pharmaceutical sector in South Africa served as a foundation for the country's engagement in vaccine manufacture. In South Africa, a number of pharmaceutical companies have the facilities and knowledge required to manufacture vaccines. A pharmaceutical company called Aspen Pharmacare produced the Johnson & Johnson COVID-19 vaccine in South Africa. In order to increase the nation's capacity for producing vaccines, Johnson & Johnson and Aspen Pharmacare entered into a technology transfer and collaboration arrangement. South Africa, along with India, proposed a temporary waiver on certain aspects of intellectual property rights related to COVID-19 vaccines, treatments, and diagnostics at the World Trade Organization (WTO). The aim was to facilitate wider access to vaccines, especially in low- and middle-income countries. South Africa has collaborated with various international organizations, including the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI), to support vaccine development and distribution efforts.

According to the research report, “South Africa Vaccine Market Overview, 2028” published by Bonafide Research, the market is anticipated to grow with 6.85% CAGR from 2023 to 2028. In South Africa, the market for vaccine has seen tremendous expansion in recent years, partly due to a number of causes, including the response to diseases that can be prevented by vaccination and rising public knowledge. A culture of vaccine use has been established as a result of the persistent attempts to preserve the public health through immunization. Public awareness has played a crucial role in this growing market. Increased access to information through various media channels and healthcare campaigns has empowered individuals to make informed decisions about their health. Government initiatives have been instrumental in driving vaccine utilization in South Africa. The government has not only invested in healthcare infrastructure and distribution networks but has also actively promoted vaccination through public health campaigns. These campaigns often target vulnerable populations and emphasize the benefits of immunization, not only for individuals but for the entire community. These initiatives have grown over time to cover standard childhood immunizations, vaccinations against COVID-19, and immunizations against other infectious diseases like hepatitis B and influenza. Moreover, the government's engagement in vaccine development, production, and distribution has been pivotal. Partnerships with pharmaceutical companies, technology transfer agreements, and the local manufacturing of vaccines have not only ensured a steady supply but have also boosted the country's self-reliance in this critical area.

In South Africa, the vaccine market in 2022 witnessed a notable dominance of conjugated vaccines, closely followed by live attenuated vaccine and recombinant vaccines. The coexistence of conjugated and recombinant vaccines in Saudi Arabia's vaccine market underscores the nation's commitment to comprehensive healthcare, particularly in protecting vulnerable populations. This combination of traditional and cutting-edge vaccine technologies ensures that Saudi Arabia can address both historical vaccine-preventable diseases and emerging health threats effectively, thus contributing to the overall health and well-being of its population.

In South Africa, the vaccine market in 2022 exhibited a significant dominance of conjugated vaccines, with live attenuated vaccines and recombinant vaccines following closely behind. Conjugated vaccines, known for their efficacy in preventing bacterial infections, particularly among young children, held a prominent position in the country's immunization programs. These vaccines have played a pivotal role in safeguarding South Africa's population against diseases. Simultaneously, live attenuated vaccines, which contain weakened forms of pathogens, were also influential in the South African vaccine market. These vaccines are highly effective in providing long-lasting immunity and have been crucial in combating diseases like measles, mumps, and rubella. Their ability to mimic natural infections without causing severe illness has made them a valuable tool in South Africa's vaccination efforts. In addition to conjugated and live attenuated vaccines, recombinant vaccines have gained prominence in the South African market. These vaccines, developed through genetic engineering techniques, are known for their precision and safety. They have proven effective in preventing diseases such as hepatitis B, offering a reliable option for immunization.

By the Type of Vaccines, the market is segmented into Multivalent and Monovalent Vaccines. To protect effectively, some vaccines require multiple antigens of one pathogen or different pathogen serotypes/serogroups in combination (multivalent or polyvalent vaccines). Multivalent vaccines and monovalent vaccines each hold distinct importance in the field of immunization, catering to different aspects of disease prevention. While multivalent vaccines are more commonly used in many vaccination programs, both types play crucial roles in safeguarding public health. Multivalent vaccines are designed to protect against multiple diseases or strains within a single vaccine shot. They offer the advantage of convenience, reducing the number of vaccinations individuals need to receive. These vaccines simplify vaccination schedules, improve compliance, and help control the spread of multiple diseases efficiently. On the other hand, monovalent vaccines are specifically tailored to protect against a single disease or pathogen. They are valuable when dealing with diseases where the pathogen exhibits significant variations, or when targeting a specific health threat, such as a new emerging infectious disease or a disease with a complex structure. Monovalent vaccines offer precision in immunization, ensuring focused protection against a particular threat. The choice between multivalent and monovalent vaccines depends on several factors, including the epidemiology of the disease, the population's susceptibility, and the availability of effective vaccines. Both types contribute to the success of vaccination programs and the reduction of disease burden. Multivalent vaccines provide broad protection, while monovalent vaccines offer tailored defense when needed.

In South Africa, the segmentation of the vaccine market based on disease types plays a pivotal role in shaping the overall growth and dynamics of the industry. This categorization encompasses a wide range of diseases, each requiring specialized vaccines for prevention. Among the notable disease segments, Pneumococcal diseases hold a significant place due to the country's focus on reducing pneumonia and related infections, especially among children and the elderly. Additionally, the vaccination against cancer, particularly cervical cancer through Human Papilloma Virus (HPV) vaccines, has gained prominence in South Africa's healthcare landscape. Influenza vaccines also play a crucial role, especially during flu seasons, contributing to public health efforts. The prevention of childhood diseases like Rotavirus, Diphtheria, Pertussis, and Tetanus (DTP) remains a priority, aligning with global immunization objectives. Addressing other disease segments such as Shingles, Meningococcal diseases, Hepatitis, Varicella (Chicken Pox), Mumps, and many more underscores the country's comprehensive approach to healthcare. South Africa's vaccination programs strive to protect its diverse population from a broad spectrum of infectious diseases, including those less common but potentially severe.

Considered in this report:
• Geography: South Africa
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• South Africa Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology:
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines

By Route of Administration:
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.)

By End-User:
• Paediatric Vaccines
• Adult Vaccines

By End-User:
• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.)

By Type:
• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Institutional Sales
• Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.